However, if your vial contains tirzepatide at 30 mg/mL, that same 0.5 mL draw contains 15 mg of active peptide
December 2025: The Judicial Panel on Multidistrict Litigation (JPML) has approved a new group lawsuit for people who experienced vision loss after taking Mounjaro and other GLP-1s
American Diabetes Association: Medications for Type 2 Diabetes Obesity Action Coalition: Lifestyle Habits to Treat Obesity Centers for Disease Control and Prevention: About Insulin Resistance Sandy Bassin, MD Medical Reviewer Sandy Bassin, MD, is an endocrinology fellow at Mount Sinai in New York City
Advise your physician if you need to take these medications for more than two weeks
Acronyms A1C - Hemoglobin A1C ADA - American Diabetes Association CVD - Cardiovascular disease DM - Diabetes mellitus FBS - Fasting blood sugar GFR - Glomerular filtration rate GI - Gastrointestinal GLP-1 - Glucagon-like peptide-1 OSA - Obstructive sleep apnea RCT - Randomized controlled trial T2DM - Type 2 diabetes mellitus Thyroid C-cell tumor = Thyroid medullary tumor DRUGS IN CLASS Dual GLP-1 and GIP agonists Tirzepatide (Mounjaro) - marketed for diabetes Tirzepatide (Zepbound) - marketed for weight loss MECHANISM OF ACTION GLP-1 and GIP GLP-1 stands for "glucagon-like peptide-1," and GIP stands for "glucose-dependent insulinotropic polypeptide." GIP is also sometimes referred to as "gastric inhibitory polypeptide." GLP-1 and GIP are hormones secreted by specialized cells in the small intestine in response to food consumption
Never stop tirzepatide (Mounjaro, Zepbound) on your own, and discuss any change to your therapy with a qualified doctor